Elicera Therapeutics AB (publ)
Stockholm Stock ExchangeTotal Valuation
Elicera Therapeutics AB (publ) carries a market capitalization of 138.42M, placing it among publicly traded companies globally.
| Market Cap | 138.42M |
| Enterprise Value | N/A |
Share Statistics
Elicera Therapeutics AB (publ) currently has 49.81M shares outstanding.
| Shares Outstanding | 49.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -87.54 |
| P/TBV Ratio | 14.45 |
| P/FCF Ratio | -9.52 |
| P/OCF Ratio | -9.52 |
Financial Position
Elicera Therapeutics AB (publ) maintains a current ratio of 8.04, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.04 |
| Quick Ratio | 6.87 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,081.28 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -42.96 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 18.17 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Elicera Therapeutics AB (publ)'s stock has declined approximately -47.02602% over the past 52 weeks. The 50-day moving average sits at 2.90, while the 200-day moving average is 5.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | -47.02602% |
| 50-Day Moving Average | 2.90 |
| 200-Day Moving Average | 5.01 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.99M, while operating income came in at -14.99M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -14.99M |
| Pretax Income | -14.45M |
| Net Income | -14.45M |
| EBITDA | -14.99M |
| EBIT | -14.99M |
| Earnings Per Share (EPS) | -0.29 |
Balance Sheet
Total book value stands at -3.02M, with working capital of 18.30M providing operational flexibility.
| Cash & Cash Equivalents | 17.86M |
| Total Debt | N/A |
| Net Debt | -17.86M |
| Equity (Book Value) | -3.02M |
| Book Value Per Share | -0.06 |
| Working Capital | 18.30M |
Cash Flow
Elicera Therapeutics AB (publ) produced -27.79M in operating cash flow over the past twelve months.
| Operating Cash Flow | -27.79M |
| Capital Expenditures | N/A |
| Free Cash Flow | -27.79M |
| FCF Per Share | -0.56 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -10.51 |
Scores
Elicera Therapeutics AB (publ) posts an Altman Z-Score of 59.41, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 59.41 |